drugset / Trial / NCT02695797

Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody

NCT02695797

Phase 4 Unknown 40 enrolled Seoul National University Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to investigate effect of immunotherapy in intractable cryptogenic epilepsy patients with autoimmune antibody.

Timeline

Start
2015-09
Primary completion
2016-12
Completion
2016-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 400 mg/kg Intravenous
Subject Prednisolone Other / unclassified 60 mg Oral

Indications